Fig. 2: BCG+1xH107e co-administration provides long-term protection on par with BCG+3xH107e.
From: A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG
a Study design comparing short- and long-term protective efficacy of a 3-dose versus 1-dose BCG+H107e/CAF®01 co-administration regimen. Red syringe: BCG; blue syringe: H107e/CAF®01. pfv: post final vaccination, pchl: post challenge. Created with Biorender. b Lung bacterial loads 4 weeks after Mtb challenge. c Lung bacterial loads 20 weeks after Mtb challenge. In (b) and (c), line and error bars indicate mean and SEM (n = 5–8). Statistical significance of group differences was determined via one-way ANOVA and Tukey’s multiple comparison test.
